SELECTIVE INHIBITOR OF EXON 18 AND/OR EXON 21 MUTANT EGFR

• 收藏
• 分享

专利权人:

TAIHO PHARMACEUTICAL CO.; LTD.

发明人:

ABE, Naomi,HASAKO, Shinichi

申请号：

SG11202001861W

公开号：

SG11202001861WA

申请日:

2018.08.31

申请国别(地区):

SG

年份:

2020

代理人:

摘要：

An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/